Posters

Comparison of visual and anatomic outcomes of ranibizumab, aflibercept and dexamethasone implant after switch from bevacizumab in retinal vein occlusions

Poster Details

First Author: J.Hanhart ISRAEL

Co Author(s):    D. Zadok                             

Abstract Details



Purpose:

To determine and compare the visual and anatomic outcomes of eyes with macular edema secondary to retinal vein occlusion after switching therapy from bevacizumab to ranibizumab, aflibercept or dexamethasone implant.

Setting:

Single retinal unit, Ophthalmology Department, Shaare Zedek Medical centre, Jerusalem.

Methods:

37 eyes (37 patients) were included in this retrospective study: 15 eyes were switched to ranibizumab, 12 to aflibercept and 10 to dexamethasone. At 3,6 9 and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT) compared with baseline and pre-switch values.

Results:

The three groups were balanced at baseline and at switch. CMT had decreased from 430.11 ± 91.21 μm to 291.86 ± 43.87 μm (P < .001) one year after the switch. VA increased in 59.5% of the eyes, overall from 0.36 ± 0.20 to 0.50 ± 0.26 (P < .001). There was no differences between the groups in the CMT and VA outcomes at one year. We found a significant difference in the number of injections: 3.30 ±0.95 for dexamethasone, 6.50 ±2.11 for aflibercept and 8.27 ±2.37 for ranibizumab (P < .001).

Conclusions:

Most of the eyes that failed initial bevacizumab therapy benefit from switching to another modality. The number of required injections during the first year after the switch varies: 3.3 with dexamethasone, 6.5 with aflibercept and 8.3 with ranibizumab.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy